Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 10/20 | 0.70 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.70 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.70 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.70 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.70 |
| ▸ | MAPT | P10636 | 2/20 | 0.70 |
| ▸ | ESR1 | P03372 | 2/20 | 0.70 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.70 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.70 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.70 |
| ▸ | SHBG | P04278 | 1/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | PGR | P06401 | 1/20 | 0.70 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.70 |
| ▸ | AR | P10275 | 1/20 | 0.70 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.70 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6869676 | 1.00 | STS (0.70) | STSABCC4CYP2C9ABCC1SLCO1B1 | |
| SCHEMBL17515290 | 0.93 | STS (0.61) | STSABCC4CYP2C9ABCC1SLCO1B1 | |
| SCHEMBL8408458 | 0.89 | STS (0.71) | STSABCC4CYP2C9ABCC1SLCO1B1 | |
| Estrone SCHEMBL22847 | 0.85 | STS (0.91) | STSABCC4CYP2C9ABCC1SLCO1B1 | |
| Estrone SCHEMBL6693553 | 0.85 | STS (0.91) | STSABCC4CYP2C9ABCC1SLCO1B1 | |
| Estrone SCHEMBL669802 | 0.84 | STS (0.89) | STSABCC4CYP2C9ABCC1SLCO1B1 | |
| Estrone SCHEMBL22551313 | 0.84 | STS (0.89) | STSABCC4CYP2C9ABCC1SLCO1B1 | |
| SCHEMBL22382721 | 0.84 | STS (0.73) | STSABCC4CYP2C9ABCC1SLCO1B1 | |
| Estrone SCHEMBL8901907 | 0.84 | STS (0.89) | STSABCC4CYP2C9ABCC1SLCO1B1 | |
| SCHEMBL27464072 | 0.84 | STS (0.76) | STSABCC4CYP2C9ABCC1SLCO1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160039866-A1 | 16- AND 17- DEUTERATED ESTROGEN-3-SULFAMATES AS ESTROGENIC AGENTS | UNIVERSITY OF BATH (GB) | 2016-02-11 | — | — | US | disclosed |
| EP-1996604-B1 | STEROIDAL COMPOUNDS AS STEROID SULPHATASE INHIBITORS | STERIX LTD (GB) | 2013-09-25 | — | — | EP | disclosed |
| CN-101395171-B | Steroids as steroid sulphatase inhibitors | STERIX LTD | 2012-10-31 | — | — | CN | disclosed |
| US-8124614-B2 | Steroidal compounds for inhibiting steroid sulphatase | STERIX LIMITED (GB) | 2012-02-28 | — | — | US | disclosed |
| US-8003783-B2 | Steroid 17 beta -hydroxysteroid dehydrogenase inhibitors substituted with one or more oxime groups, especially aromatase inhibitors used in the treatment of endocrine-dependent tumors, especially breast cancer | STERIX LIMITED (GB) | 2011-08-23 | — | — | US | disclosed |
| US-7968561-B2 | Steroidal compounds as steroid sulphatase inhibitors | STERIX LIMITED (GB) | 2011-06-28 | — | — | US | disclosed |
| US-7846965-B2 | a non-steroidal sulphamate compound such as 6-Oxo-8,9,10,11-tetrahydro-7H-cyclohepta-[c][1]benzopyran-3-O-sulphamate, suitable for use as an inhibitor of estrone sulphatase, for the treatment of endocrine-dependent cancers and tumors, such as the breast and endometrium | STERIX LIMITED (GB) | 2010-12-07 | — | — | US | disclosed |
| US-20100197647-A1 | COMPOUNDS THAT INHIBIT OESTRONE SULPHATASE; COMPOSITIONS THEREOF; AND METHODS EMPLOYING THE SAME | STERIX LIMITED (GB) | 2010-08-05 | — | — | US | disclosed |
| US-20100105764-A1 | USE | STERIX LIMITED (GB) | 2010-04-29 | — | — | US | disclosed |
| US-20090182000-A1 | STEROIDAL COMPOUNDS AS STEROID SULPHATASE INHIBITORS | RICHTER GEDEON NYRT. (HU) | 2009-07-16 | — | — | US | disclosed |
| US-6506792-B1 | Breast and endometrial cancers are major causes of death in Western women. In particular, tumours in endocrine-dependent tissues, such as the breast and endometrium, occur most frequently in postmenopausal women at a time when the ovaries | STERIX LIMITED (GB) | 2003-01-14 | — | — | US | disclosed |
| WO-2002032409-A2 | USE OF COMPOUND IN THE MANUFACTURE OF A PHARMACEUTICAL FOR INHIBITING STEROID SULPHATASE AND STEROID DEHYDROGENASE ACTIVITY | STERIX LIMITED (GB) | 2002-04-25 | — | — | WO | disclosed |
| US-6239169-B1 | ANTICARCINOGENIC AGENTS; AUTOIMMUNE DISEASES | STERIX LIMITED (GB) | 2001-05-29 | — | — | US | disclosed |
| US-6083978-A | SULPHAMOYLATING A FLAVONE, ISOFLAVONE OR A FLAVANONE; OESTRONE SULFATASE OR AROMATASE INHIBITOR | STERIX LIMITED (GB) | 2000-07-04 | — | — | US | disclosed |
| EP-0942919-A2 | COMPOUND | IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY & MEDICINE (GB) | 1999-09-22 | — | — | EP | disclosed |
| EP-0885211-A1 | COMPOUNDS WITH A SULFAMATE GROUP | IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY & MEDICINE (GB) | 1998-12-23 | — | — | EP | disclosed |
| EP-0880514-A1 | NON-STEROIDAL POLYCYCLIC RING SULPHAMATE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS OESTRONE SULPHATASE INHIBITORS | IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY & MEDICINE (GB) | 1998-12-02 | — | — | EP | disclosed |
| WO-1998024802-A2 | COMPOUND | IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE (GB) | 1998-06-11 | — | — | WO | disclosed |
| WO-1997032872-A1 | COMPOUNDS WITH A SULFAMATE GROUP | IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE (GB) | 1997-09-12 | — | — | WO | disclosed |
| WO-1997030041-A1 | NON-STEROIDAL POLYCYCLIC RING SULPHAMATE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS OESTRONE SULPHATASE INHIBITORS | IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE (GB) | 1997-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039866-A1 | 16- AND 17- DEUTERATED ESTROGEN-3-SULFAMATES AS ESTROGENIC AGENTS | ESR1, ESR2, HSD17B11 | STS 7/4885ABCC4 2398/4885CYP2C9 1507/4885 |
| US-20100197647-A1 | COMPOUNDS THAT INHIBIT OESTRONE SULPHATASE; COMPOSITIONS THEREOF; AND METHODS EMPLOYING THE SAME | CYP19A1, SHBG, CYP21A2 | STS 6/4885ABCC4 2521/4885CYP2C9 165/4885 |
| US-20090182000-A1 | STEROIDAL COMPOUNDS AS STEROID SULPHATASE INHIBITORS | STS, SULT1E1, CYP17A1 | STS 1/4885ABCC4 319/4885CYP2C9 108/4885 |
| US-20100105764-A1 | USE | HSD17B11, CYP19A1, CYP17A1 | STS 15/4885ABCC4 886/4885CYP2C9 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.